Note 15 - Segments (Tables)

9 Months Ended

Sep. 30, 2018

T hree Months Ended September 30, 2018	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	2,382		$	—		$	—		$	2,382
License revenue		19,930			—			—			19,930
Grant and other revenue		65,505			143,641			—			209,146
Total revenue		87,817			143,641			—			231,458
Cost of revenue		38,101			—			—			38,101
Research and development expenses		711,355			514,415			—			1,225,770
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			20,532			2,630,581			2,651,113
Depreciation and amortization (2)		—			—			37,590			37,590
Loss from operations (3)		(661,639	)		(391,306	)		(2,668,171	)		(3,721,116	)
Other expense (4)		—			—			(24,534	)		(24,534	)
Income tax expense		(10,081	)		(3,879	)		(62,299	)		(76,259	)
Net loss from continuing operations		(671,720	)		(395,185	)		(2,755,004	)		(3,821,909	)
Net loss		(671,720	)		(395,185	)		(2,755,004	)		(3,821,909	)
Total assets, net of depreciation and amortization:
United States	$	117,722		$	72,622		$	8,899,301		$	9,089,645
International		18,239			—			1,158			19,397
Capital expenditures		—			—			16,152			16,152

T hree Months Ended September 30, 2017	Diagnostics			Therapeutics			Corporate			Total
Grant and other revenue	$	210,479		$	13,190		$	—		$	223,669
Research and development expenses		734,539			140,008			—			874,547
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			13,359			1,671,022			1,684,381
Depreciation and amortization (2)		—			—			50,326			50,326
Loss from operations (3)		(524,060	)		(140,177	)		(1,721,348	)		(2,385,585	)
Other income		—			—			69,071			69,071
Income tax benefit		175,496			46,942			553,312			775,750
Net loss from continuing operations		(348,564	)		(93,235	)		(1,098,965	)		(1,540,764	)
Income from discontinued operations, net of tax		5,399			—			—			5,399
Gain on sale of discontinued operations, net of tax		145,877			—			—			145,877
Net loss		(197,288	)		(93,235	)		(1,098,965	)		(1,389,488	)
Total assets, net of depreciation and amortization:
United States	$	14,675,489		$	10,591		$	7,835,426		$	22,521,506
International		82,334			—			1,867			84,201
Capital expenditures		—			—			23,247			23,247

Nine Months Ended September 30, 2018	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	9,842		$	—		$	—		$	9,842
License revenue		277,639			—			—			277,639
Grant and other revenue		454,830			307,719			—			762,549
Total revenue		742,311			307,719			—			1,050,030
Cost of revenue		73,811			—			—			73,811
Research and development expenses		2,409,524			957,920			—			3,367,444
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			45,769			6,095,617			6,141,386
Depreciation and amortization (2)		—			—			113,088			113,088
Loss from operations (3)		(1,741,024	)		(695,970	)		(6,208,705	)		(8,645,699	)
Other expense (4)		—			—			(4,284,014	)		(4,284,014	)
Income tax expense		(8,797	)		(3,517	)		(53,017	)		(65,330	)
Net loss from continuing operations		(1,749,821	)		(699,487	)		(10,545,736	)		(12,995,043	)
Loss from discontinued operations, net of tax		(1,938	)		—			—			(1,938	)
Gain on sale of discontinued operations, net of tax		43,053			—			—			43,053
Net loss		(1,708,706	)		(699,487	)		(10,545,736	)		(12,953,928	)
Total assets, net of depreciation and amortization:
United States	$	117,722		$	72,622		$	8,899,301		$	9,089,645
International		18,239			—			1,158			19,397
Capital expenditures		—			—			19,317			19,317

Nine Months Ended September 30, 2017	Diagnostics			Therapeutics			Corporate			Total
License revenue	$	100,000		$	—		$	—		$	100,000
Grant and other revenue		1,200,216			115,082			—			1,315,298
Total revenue		1,300,216			115,082			—			1,415,298
Research and development expenses		2,255,842			509,853			—			2,765,695
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			19,342			8,789,728			8,809,070
Depreciation and amortization (2)		—			—			197,655			197,655
Loss from operations (3)		(955,626	)		(414,113	)		(8,987,383	)		(10,357,122	)
Other expense (4)		—			—			(1,061,190	)		(1,061,190	)
Income tax benefit		323,149			140,034			3,397,972			3,861,156
Net loss from continuing operations		(632,477	)		(274,079	)		(6,650,601	)		(7,557,156	)
Loss from discontinued operations, net of tax		(332,838	)		—			—			(332,838	)
Gain on sale of discontinued operations, net of tax		86,894,000			—			—			86,894,000
Net income (loss)		85,928,685			(274,079	)		(6,650,601	)		79,004,006
Total assets, net of depreciation and amortization:
United States	$	14,675,489		$	10,591		$	7,835,426		$	22,521,506
International		82,334			—			1,867			84,201
Capital expenditures		—			—			31,417			31,417